Niraparib is a potent, selective and orally available PARP 1/2 inhibitor with IC50 values of 3.8 and 2.1 nM, respectively. Moreover, in a whole cell assay, Niraparib inhibited PARP activity with an EC50 value of 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 (CC50 value of 10−100 nM). Niraparib was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.

KEYWORDS: Niraparib | supplier | PARP inhibitor | MK 4827 | MK4827 | MK-4827 | CAS [1038915-60-4] | CAS [1038915-64-8] | CAS [1038915-73-9] | DNA-RNA | PARP | Inhibitor | Enzymes | BRCA